Survival benefits from postoperative radiation therapy on lymph node positive patients with pancreatic adenocarcinoma.
Survival benefits from postoperative radiation therapy on lymph node positive patients with pancreatic adenocarcinoma.
复制标题
淋巴结阳性胰腺癌患者术后放疗的生存获益
DOI：
10.18632/oncotarget.9620
复制
发表时间：
2016-07-19
期刊：
影响因子：
--
通讯作者：
Mao Y
中科院分区：
文献类型：
--
作者：
Xia Z;Jia X;Chen K;Li D;Xie J;Xu H;Mao Y
胰腺癌术后放疗联合化疗的益处存在争议。我们试图确定PORT对接受原发部位手术的胰腺癌患者生存率的影响。从监测、流行病学和最终结果（SEER）数据库中确定了1988年至2012年间接受原发性肿瘤手术的胰腺癌患者。我们评估了PORT与其他临床病理因素和生存率之间的关系。总共确定了5304例接受胰腺切除术的患者，包括2093例PORT患者和3211例未PORT患者。中位总生存期、癌症特异性生存期和其他原因生存期分别为19.0、20.0和196.0个月，有PORT组与无PORT组分别为14.0、15.0和163.0个月（均P < 0.001）。亚组分析显示PORT的获益仅限于N1疾病患者。N1疾病患者的中位总生存期、癌症特异性生存期和其他原因生存期分别为18.0、18.0和NA个月，PORT组与非PORT组分别为12.0、13.0和154.0个月（均P < 0.001）。无论阳性淋巴结计数（PLN）和淋巴结比率（LNR）的数量，PORT总是与N1疾病患者的生存率增加相关（所有P < 0.001）。总之，PORT对淋巴结阳性的胰腺癌患者可能具有生存获益。
The benefit of combining postoperative radiation therapy (PORT) with chemotherapy for resected patients with pancreatic adenocarcinoma is controversial. We sought to determine the effects of PORT on survival in patients with pancreatic adenocarcinoma who underwent primary site surgery. Patients with pancreatic adenocarcinoma receiving primary tumor surgery between 1988 and 2012 were identified from the Surveillance, Epidemiology and End Results (SEER) database. We estimated the association between PORT and other clinicopathologic factors and survival. In total, 5304 patients were identified who underwent pancreatic resection including 2093 patients who had PORT and 3211 patients who had no PORT. Median overall, cancer-specific, and other-cause survival were 19.0, 20.0, and 196.0 months, respectively, with PORT versus 14.0, 15.0, and 163.0 months, respectively, without PORT (all P < 0.001). Subset analysis revealed that the benefit of PORT was limited to patients with N1 disease. Median overall, cancer-specific, and other-cause survival for patients with N1 disease were 18.0, 18.0, and NA months, respectively, with PORT versus 12.0, 13.0, and 154.0 months, respectively, without PORT (all P < 0.001). Regardless the number of positive lymph node count (PLN) and lymph node ratio (LNR), PORT was always associated with increased survival on multivariate analysis in patients with N1 disease (all P < 0.001). In summary, survival benefits might be obtained from PORT on lymph node positive patients with pancreatic adenocarcinoma.
登录
查看更多内容
影响因子：
4.3
作者：
Chen, Yue;Sun, Xian-Jun;Mao, Ai-Wu
通讯作者：
Mao, Ai-Wu
影响因子：
9
作者：
Morak, Marjolein J. M.;van der Gaast, Ate;van Eijck, Casper H. J.
通讯作者：
van Eijck, Casper H. J.
影响因子：
8.8
作者：
通讯作者：
--
影响因子：
45.3
作者：
Van Laethem, Jean-Luc;Hammel, Pascal;Haustermans, Karin
通讯作者：
Haustermans, Karin
影响因子：
3.7
作者：
Bilimoria, Karl Y.;Stewart, Andrew K.;Bentrem, David J.
通讯作者：
Bentrem, David J.